Literature DB >> 3484642

Cell-mediated amegakaryocytic thrombocytopenia associated with systemic lupus erythematosus.

T Nagasawa, T Sakurai, H Kashiwagi, T Abe.   

Abstract

We studied a patient with a rare complication of amegakaryocytic thrombocytopenia (AMT) associated with systemic lupus erythematosus (SLE). To investigate the underlying pathogenesis of AMT, the effects of peripheral blood T cells and serum on human megakaryocyte progenitor cells were studied using in vitro coculture techniques. Mononuclear bone marrow cells (2 X 10(5) from normal donors produced 33.6 +/- 8.8 (n = 10) colony-forming unit-megakaryocytes (CFU-M) in our plasma clot system. When 2 X 10(5) of the patient's T cells were added to the culture system, the number of CFU-M decreased to only 3.5 +/- 0.6/2 X 10(5) bone marrow cells. No evidence of inhibitory effects was found by the addition of the patient's serum and complement to the culture system. The T cells stored at -80 degrees C on admission were also capable of suppressing autologous CFU-M after recovery from AMT. These results indicate that in vitro suppression of CFU-M from allogenic and autologous bone marrow cells by this patient's T cells provides an explanation for the pathogenesis of AMT associated with SLE.

Entities:  

Mesh:

Year:  1986        PMID: 3484642

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Successful treatment of acquired amegakaryocytic thrombocytopenia with cyclosporine in adult onset Still's disease.

Authors:  Min-Young Her; Tae-Hwan Kim; Hyun-Kyu Chang; Woong-Soo Lee; Dae-Hyun Yoo
Journal:  Rheumatol Int       Date:  2006-09-07       Impact factor: 2.631

2.  Therapeutic effect of cyclosporine A in thrombocytopenia after myeloablative chemotherapy in acute myeloid leukaemia.

Authors:  Y Novik; L Oleksowicz; P H Wiernik
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

3.  Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light-chain immunoglobulin.

Authors:  J E Hopper; W Sequeira; J Martellotto; E Papagiannes; L Perna; J L Skosey
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

4.  Successful treatment of acquired amegakaryocytic thrombocytopenic purpura refractory to corticosteroids and intravenous immunoglobulin with antithymocyte globulin and cyclosporin.

Authors:  Pimjai Niparuck; Vichai Atichartakarn; Suporn Chuncharunee
Journal:  Int J Hematol       Date:  2008-07-15       Impact factor: 2.490

5.  Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide.

Authors:  A M Gewirtz; B Calabretta; B Rucinski; S Niewiarowski; W Y Xu
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

6.  Human megakaryocytic progenitor cells.

Authors:  L Kanz; G W Löhr; A A Fauser
Journal:  Klin Wochenschr       Date:  1987-04-01

7.  Myelodysplastic Syndrome Presenting as Amegakaryocytic Thrombocytopenia in a Collodion Baby.

Authors:  Mohammed Al Pakra; Abdullah Al Jabri; Ehab Hanafy
Journal:  J Investig Med High Impact Case Rep       Date:  2015-09-10

8.  Acquired Amegakaryocytic Thrombocytopenia in Adult-onset Still's Disease: Successful Combination Therapy with Tocilizumab and Cyclosporine.

Authors:  Takanori Ichikawa; Yasuhiro Shimojima; Toshiaki Otuki; Ken-Ichi Ueno; Dai Kishida; Yoshiki Sekijima
Journal:  Intern Med       Date:  2019-08-06       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.